INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 May 2017
Net Assets |
£227m |
Net Assets per share |
603p |
Share price |
572p |
Total value of unquoted investments |
£23m |
Total number of portfolio companies |
91 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Celgene |
7.6 |
Regeneron |
7.6 |
Genmab |
5.6 |
Vertex |
5.5 |
Biogen |
5.2 |
Shire |
4.0 |
Alexion |
3.6 |
Incyte |
3.4 |
Aerie |
2.9 |
Biomarin |
2.8 |
|
----------- |
Total |
48.2 |
Geographical Allocation |
% NAV |
US & Canada |
80 |
Europe & UK |
20 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
90 |
Unquoted |
10 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
53 |
Mid Cap =USD1-10BN |
22 |
Small Cap <USD1BN |
25 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
34 |
Orphan |
13 |
CNS |
11 |
Ophthalmology |
11 |
Inflammation |
7 |
Medtech |
2 |
Other |
22 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
14 JUNE 2017